Biomarker for Infection Risk in Chronic Lymphocytic Leukemia and Multiple Myeloma

Inclusion Criteria

• * Adults ≥ 18 years of age. * Diagnosis of Rai stage I-IV chronic lymphocytic leukemia or small lymphocytic lymphoma or multiple myeloma by WHO criteria * Subjects must be able to consent to clinical trial, or documented health care proxy agent able to consent on behalf of participant

Exclusion Criteria

• * Subjects must not have received IVIG administration within 6 calendar months of registration or have planned IVIG infusion by treating investigator at time of registration * Subjects with chronic lymphocytic leukemia or small lymphocytic lymphoma must not be Rai stage 0 * Subjects with multiple myeloma must not have smoldering myeloma or solitary plasmacytoma with or without minimal marrow involvement * Subjects must not have undergone prior autologous, allogeneic stem cell, or solid organ transplant * Subjects must not have any active systemic infection requiring ongoing antimicrobial treatment (prophylactic antimicrobial allowed) at time of registration * Subjects must have no known history of HIV, primary immune deficiency disorder, nor be taking a concurrent immune suppressing medication at time of registration. Treatment for CLL/SLL or MM, CLL/SLL related autoimmune phenomenon, or physiologic dosing of corticosteroids (5mg/day prednisone/equivalent or lower) is permitted